References
- Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257:107-26. ISSN 1600-065X. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24329793; PMID:24329793; https://doi.org/10.1111/imr.12131
- Geyer MB, Brentjens RJ. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy 2016; 18(11):1393-1409. ISSN 1477-2566. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27592405; PMID:27592405
- Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17. ISSN 1533-4406. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25317870; PMID:25317870; https://doi.org/10.1056/NEJMoa1407222
- Chen R, Song XT, Chen B. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia. Discov Med 2015; 20:185-90. ISSN 1944-7930. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26562471; PMID:26562471
- Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18. ISSN 1533-4406. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/23527958; PMID:23527958; https://doi.org/10.1056/NEJMoa1215134
- Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12:6106-15. ISSN 1078-0432. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/17062687; PMID:17062687; https://doi.org/10.1158/1078-0432.CCR-06-1183
- Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118:6050-6. ISSN 1528-0020. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21984804; PMID:21984804; https://doi.org/10.1182/blood-2011-05-354449
- Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013; 21:904-12. ISSN 1525-0024. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/23423337; PMID:23423337; https://doi.org/10.1038/mt.2013.17
- Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989; 86:10024-8. ISSN 0027-8424. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/2513569 >
- Pegram HJ, Park JH, Brentjens RJ. CD28z CARs and armored CARs. Cancer J 2014; 20:127-33, ISSN 1540-336X. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24667958; PMID:24667958; https://doi.org/10.1097/PPO.0000000000000034
- Makkouk A, Chester C, Kohrt HE. Rationale for anti-CD137 cancer immunotherapy. Eur J Cancer 2016; 54:112-9. ISSN 1879-0852. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26751393; PMID:26751393; https://doi.org/10.1016/j.ejca.2015.09.026
- Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21:581-90. ISSN 1546-170X. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25939063; PMID:25939063; https://doi.org/10.1038/nm.3838
- Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73. ISSN 1946-6242. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21832238; PMID:21832238; https://doi.org/10.1126/scitranslmed.3002842
- Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ, Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012; 119:696-706. ISSN 1528-0020. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/22117050; PMID:22117050; https://doi.org/10.1182/blood-2011-03-344275
- Hombach AA, Abken H. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Immunotherapy 2013; 5:677-81. ISSN 1750-7448. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/23829616; PMID:23829616; https://doi.org/10.2217/imt.13.54
- Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD, Jr, Scholler J, Scholler N, et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 2014; 124:1070-80. ISSN 1528-0020. Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed/24986688; PMID:24986688; https://doi.org/10.1182/blood-2013-10-535245
- Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 2014; 257:91-106. ISSN 1600-065X. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24329792; PMID:24329792; https://doi.org/10.1111/imr.12126
- Chmielewski M, Abken H. Trucks: the fourth generation of CARs. Expert Opin Biol Ther 2015; 15:1145-54. ISSN 1744-7682. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25985798; PMID:25985798; https://doi.org/10.1517/14712598.2015.1046430
- Smith AJ, Oertle J, Warren D, Prato D. Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective. Journal of Cellular Immunotherapy 2016; 2(2):59-68; https://doi.org/10.1016/j.jocit.2016.08.001
- Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, et al. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. J Natl Cancer Inst 2015; 107:364. ISSN 1460-2105. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25424197; PMID:25424197; https://doi.org/10.1093/jnci/dju364
- Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, Chen IS, Yang OO, Zack JA, Kitchen SG. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther 2015; 23:1358-67. ISSN 1525-0024. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26050990; PMID:26050990; https://doi.org/10.1038/mt.2015.102
- Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 2013; 24:717-27. ISSN 1557-7422. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/23883116; PMID:23883116; https://doi.org/10.1089/hum.2013.075
- Schutsky K, Song DG, Lynn R, Smith JB, Poussin M, Figini M, Zhao Y, Powell DJ, Jr. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget 2015; 6:28911-28. ISSN 1949-2553. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26359629; PMID:26359629
- Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2:112-20. ISSN 2326-6074. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24579088; PMID:24579088; https://doi.org/10.1158/2326-6066.CIR-13-0170
- Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70:9053-61. ISSN 1538-7445. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/20926399; PMID:20926399; https://doi.org/10.1158/0008-5472.CAN-10-2880
- Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1:26-31. ISSN 2326-6074. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24777247; https://doi.org/10.1158/2326-6066.CIR-13-0006
- Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012; 120:612-8. ISSN 1873-233X. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/22914471; PMID:22914471; https://doi.org/10.1097/AOG.0b013e318264f794
- Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993; 178:361-6. ISSN 0022-1007. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/8315392; PMID:8315392; https://doi.org/10.1084/jem.178.1.361
- Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol 2011; 2011:475983. ISSN 1687-8469. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21577260; PMID:21577260; https://doi.org/10.1155/2011/475983
- Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006; 66:1181-90. ISSN 0008-5472. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/16424057; PMID:16424057; https://doi.org/10.1158/0008-5472.CAN-04-2962
- Koneru M, O'Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015; 13:102. ISSN 1479-5876. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25890361; PMID:25890361; https://doi.org/10.1186/s12967-015-0460-x
- Kandalaft LE, Powell DJ, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012; 10:157. ISSN 1479-5876. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/22863016; PMID:22863016; https://doi.org/10.1186/1479-5876-10-157
- Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Ther 2015; 22:675-84. ISSN 1476-5462. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25830550; PMID:25830550; https://doi.org/10.1038/gt.2015.29
- Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ, Jr. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 2012; 7:e49829. ISSN 1932-6203. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/23189165; PMID:23189165; https://doi.org/10.1371/journal.pone.0049829
- Mayor M, Zeltsman M, McGee E, Adusumilli PS. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial. Immunotherapy 2016; 8:491-4. ISSN 1750-7448. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27140404; PMID:27140404; https://doi.org/10.2217/imt-2016-0008
- O'Hara M, Stashwick C, Haas AR, Tanyi JL. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 2016; 8:449-60. ISSN 1750-7448. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26973126; PMID:26973126; https://doi.org/10.2217/imt.16.4
- Urbanska K, Stashwick C, Poussin M, Powell DJ, Jr. Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer. Cancer Immunol Res 2015; 3:1130-7. ISSN 2326-6074. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26112923; PMID:26112923; https://doi.org/10.1158/2326-6066.CIR-15-0047
- Mackay HJ, Provencheur D, Heywood M, Tu D, Eisenhauer EA, Oza AM, Meyer R. Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21. Curr Oncol 2011; 18:84-90. ISSN 1718-7729. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21505599; PMID:21505599; https://doi.org/10.3747/co.v18i2.725
- Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014; 6:261ra151. ISSN 1946-6242. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25378643; PMID:25378643; https://doi.org/10.1126/scitranslmed.3010162
- Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 2016; 3:16011. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27626062; PMID:27626062; https://doi.org/10.1038/mto.2016.11
- Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005; 124:838-45. ISSN 0002-9173. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/16416732; PMID:16416732; https://doi.org/10.1309/F1B64CL7H8VJKEAF
- Künkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC. Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated Due to Cell Fas-FasL-Dependent AICD. Cancer Immunol Res 2015; 3:368-79. ISSN 2326-6074. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25576337; PMID:25576337; https://doi.org/10.1158/2326-6066.CIR-14-0200
- Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 Blockade. Mol Ther 2016; 24:1135-49. ISSN 1525-0024. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27019998; PMID:27019998; https://doi.org/10.1038/mt.2016.63
- Ma SD, Xu X, Jones R, Delecluse HJ, Zumwalde NA, Sharma A, Gumperz JE, Kenney SC. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-induced lymphoma growth in a cord blood humanized-mouse model. PLoS Pathog 2016; 12:e1005642. ISSN 1553-7374. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27186886; PMID:27186886; https://doi.org/10.1371/journal.ppat.1005642
- Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183:5563-74. ISSN 1550-6606. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/19843940; PMID:19843940; https://doi.org/10.4049/jimmunol.0900447
- Liang WC, Liang PP, Wong CW, Ng TB, Huang JJ, Zhang JF, Waye MM, Fu WM. Crispr/Cas9 technology targeting FAS gene protects mice from Concanavalin-A induced fulminant hepatic failure. J Cell Biochem 2016; https://www.ncbi.nlm.nih.gov/pubmed/27585307
- Chu VT, Graf R, Wirtz T, Weber T, Favret J, Li X, Petsch K, Tran NT, Sieweke MH, Berek C, et al. Efficient CRISPR-mediated mutagenesis in primary immune cells using CrispRGold and a C57BL/6 Cas9 transgenic mouse line. Proc Natl Acad Sci U S A 2016; 113(44):12514-12519. ISSN 1091-6490. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27729526; PMID:27729526; https://doi.org/10.1073/pnas.1613884113
- Dotti G, Savoldo B, Pule M, Straathof KC, Biagi E, Yvon E, Vigouroux S, Brenner MK, Rooney CM. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005; 105:4677-84. ISSN 0006-4971. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/15713795; PMID:15713795; https://doi.org/10.1182/blood-2004-08-3337
- Song L, Yang MC, Knoff J, Wu TC, Hung CF. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment. PLoS One 2014; 9:e115711. ISSN 1932-6203. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25531529; PMID:25531529; https://doi.org/10.1371/journal.pone.0115711
- Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity 2016; 44:1444-54. ISSN 1097-4180. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27332733; PMID:27332733; https://doi.org/10.1016/j.immuni.2016.05.014
- Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM, Zhao Y. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2014; 2:1059-70. ISSN 2326-6074. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25104548; PMID:25104548; https://doi.org/10.1158/2326-6066.CIR-14-0051
- Singh N, Barrett DM, Grupp SA. Roadblocks to success for RNA CARs in solid tumors. Oncoimmunology 2014; 3:e962974. ISSN 2162-4011. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25964863; PMID:25964863; https://doi.org/10.4161/21624011.2014.962974
- Beatty GL, O'Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacol Ther 2016; 166:30-9. ISSN 1879-016X. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27373504; PMID:27373504; https://doi.org/10.1016/j.pharmthera.2016.06.010
- Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology 2014; 3:e970027. ISSN 2162-4011. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25941599; PMID:25941599; https://doi.org/10.4161/21624011.2014.970027
- Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, Boutros C, Hanna N, Junghans RP. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther 2016; 23:142-8. ISSN 1476-5500. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27080226; PMID:27080226; https://doi.org/10.1038/cgt.2016.14